Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Lung cancer is a type of cancer, which starts in the lungs. There are two main types of lung cancer and they are treated differently such as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).According to American Cancer Society around 80% to 85% of lungs cancer are non-small cell lung cancer and 10% to 15% of lung cancers are small cell lung cancer. Small cell lung cancer is also called oat cell cancer. Some of the important screening tests of lung cancer includes biomarkers, imaging test, and biopsy. Major factors driving growth of the market during the forecast period (2021-2028) include increasing test approvals by regulatory bodies, investments in research, and strategic expansions by major players operating in lung cancer diagnostic and screening market to strengthen their geographical footprint. For instance, the US Food and Drug Administration approved Tagrisso as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation. Tagrisso was approved in 2018 for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.
Lung Cancer Diagnostic and Screening Market – Impact of Coronavirus (COVID-19) Pandemic
During the pandemic, lung cancer screening programs had been largely suspended. Due to shut down, there was increasing demand for cancer screening test. Prior to the pandemic, according to article published 2019 in Official Journal of the Asia Pacific Society of Respirology, lung cancer was the leading cause of cancer diagnosis and mortality worldwide, accounting for 11.6% of new cases and 18.4% of deaths. The poor prediction of symptoms of lung cancer largely credited to the majority of patients being diagnosed at an advanced stage. The pandemic witnessed a sharp drop in referrals to lung cancer services, with concerns of a surge of late?stage presentations followed by a rise in mortality rates. Due to the same indications between lung cancer and COVID-19, including cough and breathlessness, led to patients self-isolate due to concern of being infectious. Moreover public health organizations advised to remain home has resulted in hesitation to attend healthcare services. As a result, screening of lung cancer has been hampered during the pandemic.
The global lung cancer diagnostic and screening market is estimated to be valued at US$ 1,931.0 million in 2020 and is expected to exhibit a CAGR of 7.8% during the forecast period (2021-2028).
Fig. 1: Global Lung Cancer Diagnostic and Screening Market Share (%) Analysis, By Test Type, 2021-2028
Increasing R&D activities and product approvals are expected to drive growth of the global lung cancer diagnostic and screening market.
Major factors driving the market growth include rising focus on research and development of lung cancer diagnosis and screening test. For instance, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) developed a nanoparticle-based approach that allows the early diagnosis of lung cancer through a simple urine test. The strategy detects biomarkers resulting from the interaction of peptide-coated nanoparticles with disease-associated proteases in the tumor microenvironment. Experiments in two different mouse models of lung cancer showed that the urine test could detect tumors as small as 2.8 mm. The researchers hope that this type of noninvasive diagnosis could reduce the number of false positives associated with an existing test method, and help to detect more tumors in the early stages of the disease.
Furthermore, increasing adoption of inorganic growth strategies by market players such as collaborations and acquisitions are expected to boost the global lung cancer diagnostic and screening market growth in the near future. For instance, in January 2020, Amgen announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood and tissue-based companion diagnostics (CDx), respectively, for investigational cancer treatment AMG 510. AMG 510 is the first KRASG12C inhibitor to advance to the clinic for investigation in treatment of multiple tumor types. KRAS G12C is one of the most frequently mutated oncogenes in human cancer. The agreements with both companies will initially focus on CDx tests for non-small cell lung cancer (NSCLC).
Lung Cancer Diagnostic and Screening Market Report Coverage
||Market Size in 2021:
||US$ 1,931.0 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2022 to 2028 CAGR:
||2028 Value Projection:
||US$ 3,515.9 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of APAC
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Test Type:
- Biomarkers Tests: EGFR Mutation Tests, KRAS Mutation Tests, ALK Tests, HER2 Tests, Others.
- Imaging Tests: Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X- Ray, Others
- Biopsy: Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, Others
- By Cancer Type: Non-small cell lung cancer, Small Cell Lung Cancer
- By End User: Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others
Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc ., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.
- Product Approvals and Launches
- Increasing Research and Development
|Restraints & Challenges:
- Lack of awareness of lung cancer screening and false positive report
Lung Cancer Diagnostic and Screening Market – Restraints
Screening of lung cancer is done, when there is no symptoms for lung cancer. Due to these there is lack of awareness in people to perform screening. This is expected to hinder growth of the market. False positive reports are also expected to hamper growth of the market. For instance, in March 2019, Researchers at the University of Pittsburgh and UPMC Hillman cancer center found that the 96% of people who screen positive for lung cancer don’t actually have a malignant growth. These information is provided by an article published by University of Pittsburg.
Lung Cancer Diagnostic and Screening Market – Regional Analysis
On the basis of region, the global lung cancer diagnostic and screening market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to be the most dominant region in the lung cancer diagnostic and screening market during the forecast period. The increasing number of inorganic growth strategies by North America key players such as acquisitions and mergers are major factors propelling growth of the North America lung cancer diagnostic and screening market. For instance in April 2016, AbbVie, a global biopharmaceutical company, announced the acquisition of Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) currently in registrational trials for small cell lung cancer (SCLC). Rova-T is a novel biomarker-specific therapy that is derived from cancer stem cells and targets delta-like protein 3 (DLL3) that is expressed in over 80% of SCLC patient tumors and is not present in healthy tissue.
Moreover, Asia Pacific lung cancer diagnostic and screening market is expected to witness significant growth due to launch of new lung cancer screening test over the forecast period. For instance, in February 2021, AnPac Bio-Medical Science Co., Ltd, a biotechnology company with operations in China and the U.S. focused on early cancer screening and detection, announced on January 25, 2021, the National Medical Products Administration, China’s medical product regulatory authority, approved for AnPac Bio to start the registration testing of its Class III lung cancer auxiliary diagnosis medical device at a designated medical device testing laboratory, which is a significant step towards obtaining a Class III medical device registration certificate by AnPac Bio.
Fig. 2: Global Lung Cancer Diagnostic and Screening Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2028
Global Lung Cancer Diagnostic and Screening Market - Competitive Landscape
Key players operating in the global lung cancer diagnostic and screening market include Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.